About laurabbook@gmail.com

This author has not yet filled in any details.
So far laurabbook@gmail.com has created 176 blog entries.
7 September 2021

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC

2021-09-07T17:48:06-07:00

*May 2021* Note: Is further evaluation of the combination warranted for patients with locally advanced or metastatic T790M-negative, EGFR-positive NSCLC? The

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC2021-09-07T17:48:06-07:00
7 September 2021

Osimertinib Combinations as Second-Line Treatment in Non-Small Cell Lung Cancer: The Jury’s Still Out

2021-09-07T17:39:36-07:00

*July 2021* Note  Should a VEGF inhibitor (bevacizumab/Avastin) be combined with osimertinib or not? The role of osimertinib combinations as second-line treatment

Osimertinib Combinations as Second-Line Treatment in Non-Small Cell Lung Cancer: The Jury’s Still Out2021-09-07T17:39:36-07:00
7 September 2021

Efficacy and Safety of Patritumab Deruxtecan in EGFR Mutated NSCLC Resistant to EGFR TKI Therapy

2021-09-07T17:28:39-07:00

*July 2021* Patritumab deruxtecan (HER3-DXd), an antibody drug conjugate consisting of a fully human monoclonal antibody to HER3 attached to

Efficacy and Safety of Patritumab Deruxtecan in EGFR Mutated NSCLC Resistant to EGFR TKI Therapy2021-09-07T17:28:39-07:00
7 September 2021

Amivantamab/Lazertinib Combination May Overcome Osimertinib Resistance in Patients With EGFR-Positive NSCLC

2021-09-07T17:15:42-07:00

*July 2021* Combination targeting of epidermal growth factor receptor (EGFR) with amivantamab/lazertinib achieved durable responses in more than one-third of chemotherapy-naive

Amivantamab/Lazertinib Combination May Overcome Osimertinib Resistance in Patients With EGFR-Positive NSCLC2021-09-07T17:15:42-07:00
Go to Top